Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab

Area of Science:

• Oncology and Immunology
• Pulmonology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, targeting pathways like programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
• While effective in various solid tumors, ICIs can induce immune-mediated adverse events affecting multiple organ systems, including the lungs.
• Pulmonary toxicity is a significant concern, particularly in lung cancer patients where diagnosis can be complicated by disease progression and treatment effects.

Purpose of the Study:

• To comprehensively review the pulmonary adverse effects associated with nivolumab, a specific programmed death-1 (PD-1) inhibitor.
• To highlight the spectrum of lung complications that can arise from PD-1 blockade therapy.
• To inform clinicians about potential pulmonary toxicities to ensure timely diagnosis and management.

Main Methods:

• Literature review focusing on pulmonary adverse events documented for nivolumab.
• Compilation and categorization of reported lung complications.
• Analysis of the clinical presentation and implications of these toxicities.

Main Results:

• Nivolumab is associated with a range of pulmonary complications, including dyspnea, pneumonitis, pleural effusion, and various forms of pneumonia (e.g., organizing pneumonia, eosinophilic pneumonia).
• Other reported effects include pulmonary sarcoidosis, pulmonary tuberculosis, adult respiratory distress syndrome, and lung cavitation.
• These immune-mediated lung toxicities underscore the importance of vigilant monitoring in patients receiving PD-1 inhibitors.

Conclusions:

• Clinicians must maintain a high index of suspicion for pulmonary adverse events in patients treated with PD-1 inhibitors like nivolumab.
• Awareness of these potential toxicities is crucial, especially in patients with pre-existing lung conditions or lung cancer.
• Prompt recognition and management are essential to mitigate the impact of immune-related pulmonary complications.